Kintor Pharmaceutical Limited (HKG:9939)
Hong Kong
· Delayed Price · Currency is HKD 1.170
-0.040 (-3.31%)
Apr 25, 2025, 4:08 PM HKT
Kintor Pharmaceutical Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 147.42 | 445.5 | 865.08 | 930.15 | 1,066 | Upgrade
|
| Short-Term Investments | 1.27 | 12.56 | 11.88 | 126.58 | 327.53 | Upgrade
|
| Cash & Short-Term Investments | 148.69 | 458.05 | 876.96 | 1,057 | 1,393 | Upgrade
|
| Cash Growth | -67.54% | -47.77% | -17.01% | -24.15% | 607.84% | Upgrade
|
| Other Receivables | 15.65 | 6.48 | - | - | - | Upgrade
|
| Receivables | 15.65 | 6.48 | - | - | - | Upgrade
|
| Inventory | 2.22 | - | 603.5 | 351.36 | - | Upgrade
|
| Restricted Cash | 0.43 | 0.43 | 5.64 | 1.66 | - | Upgrade
|
| Other Current Assets | 4.75 | 7.6 | 21.77 | 116.15 | 27.49 | Upgrade
|
| Total Current Assets | 171.73 | 472.56 | 1,508 | 1,526 | 1,421 | Upgrade
|
| Property, Plant & Equipment | 174.23 | 221.84 | 282.48 | 262.3 | 186.68 | Upgrade
|
| Long-Term Investments | 16.57 | 18 | 17.95 | - | - | Upgrade
|
| Other Intangible Assets | 148.95 | 148.94 | 235.65 | 235.62 | 209.76 | Upgrade
|
| Other Long-Term Assets | 3.65 | 7.9 | 11.2 | 44.17 | 34.42 | Upgrade
|
| Total Assets | 515.13 | 869.23 | 2,055 | 2,068 | 1,851 | Upgrade
|
| Accounts Payable | 40.96 | 81.6 | 180.4 | 172.96 | 28.81 | Upgrade
|
| Accrued Expenses | 6.68 | 17.32 | 19.89 | 25.12 | 16.38 | Upgrade
|
| Short-Term Debt | 14.4 | 20 | 40 | - | 79.9 | Upgrade
|
| Current Portion of Long-Term Debt | 97.36 | 93.7 | 58.9 | 7.4 | 3.7 | Upgrade
|
| Current Portion of Leases | 1.25 | 4.53 | 4.44 | 2.07 | 2.71 | Upgrade
|
| Current Unearned Revenue | - | - | - | - | 0.36 | Upgrade
|
| Other Current Liabilities | 6.03 | 7.58 | 14.5 | 12.2 | 37.47 | Upgrade
|
| Total Current Liabilities | 166.68 | 224.73 | 318.13 | 219.74 | 169.33 | Upgrade
|
| Long-Term Debt | 20 | 133.4 | 177.6 | 147.5 | 134.9 | Upgrade
|
| Long-Term Leases | - | 2.29 | 5.45 | 2.76 | 0.49 | Upgrade
|
| Long-Term Unearned Revenue | 3.32 | 19.66 | 19.95 | 4.01 | - | Upgrade
|
| Long-Term Deferred Tax Liabilities | 31.04 | 31.04 | 38.82 | 38.82 | 38.82 | Upgrade
|
| Total Liabilities | 221.05 | 411.12 | 559.95 | 412.83 | 343.54 | Upgrade
|
| Common Stock | 0.32 | 0.32 | 0.32 | 0.27 | 0.26 | Upgrade
|
| Additional Paid-In Capital | - | 4,182 | 4,104 | 3,359 | - | Upgrade
|
| Retained Earnings | - | -3,785 | -2,724 | -1,769 | -927.38 | Upgrade
|
| Comprehensive Income & Other | 293.77 | 60.73 | 114.77 | 65.49 | 2,435 | Upgrade
|
| Shareholders' Equity | 294.08 | 458.11 | 1,495 | 1,655 | 1,508 | Upgrade
|
| Total Liabilities & Equity | 515.13 | 869.23 | 2,055 | 2,068 | 1,851 | Upgrade
|
| Total Debt | 133.01 | 253.92 | 286.39 | 159.73 | 221.7 | Upgrade
|
| Net Cash (Debt) | 15.68 | 204.13 | 590.57 | 897 | 1,171 | Upgrade
|
| Net Cash Growth | -92.32% | -65.43% | -34.16% | -23.43% | 782.66% | Upgrade
|
| Net Cash Per Share | 0.04 | 0.48 | 1.57 | 2.52 | 3.79 | Upgrade
|
| Filing Date Shares Outstanding | 431.02 | 439.4 | 447.5 | 387.59 | 369.39 | Upgrade
|
| Total Common Shares Outstanding | 431.02 | 439.4 | 447.5 | 387.59 | 369.39 | Upgrade
|
| Working Capital | 5.05 | 247.83 | 1,190 | 1,306 | 1,251 | Upgrade
|
| Book Value Per Share | 0.68 | 1.04 | 3.34 | 4.27 | 4.08 | Upgrade
|
| Tangible Book Value | 145.13 | 309.17 | 1,260 | 1,420 | 1,298 | Upgrade
|
| Tangible Book Value Per Share | 0.34 | 0.70 | 2.81 | 3.66 | 3.51 | Upgrade
|
| Buildings | - | 89.23 | 89.23 | 57.66 | 57.66 | Upgrade
|
| Machinery | - | 58.7 | 58.24 | 46.78 | 29.88 | Upgrade
|
| Construction In Progress | - | 109.24 | 105.66 | 125.74 | 92.29 | Upgrade
|
Updated Sep 26, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.